Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL
Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL
Upcoming trends in myeloma therapy
Recent advances in mantle cell lymphoma: Expert panel discussion
Lecture: Current use of systemic therapies in localised disease
Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (for)
Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (against)
Rituximab versus idelalisib in refractory CLL
Use of GA101 and Clb preferable to rituximab in elderly or unfit chronic lymphocytic leukaemia patients
WIN Symposium 2014: Breakthrough biomarker investigations and combination therapies
Work and history of the Kidney Cancer Association
Kidney cancer treatment ten years from now
Personalisation of leukaemia treatment using genome sequencing